Evidence map›Paper›PMID 37643378›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory

Darren R Hargrave, Keita Terashima, Junichi Hara, Uwe R Kordes, Santhosh A Upadhyaya, Felix Sahm, Eric Bouffet, Roger J Packer, Olaf Witt, Larissa Sandalic and 4 more

Open access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 7 pooled it
16.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 7 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Efficacy and safety of dabrafenib plus trametinib in pediatric versus adult gliomas: a systematic review and meta-analysis.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Review
  13. RAS/MAPK inhibition in pediatric gliomas.Neuro-oncology advances · 2026
    Review
  14. Review
  15. Review
  16. Targeted therapies in pediatric oncology: A start.Molecular therapy. Oncology · 2026
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 6 countries.

Darren R HargraveUCL Great Ormond Street Institute of Child Health, London, United Kingdom.ORCID 0000-0001-8219-9807
Keita TerashimaNational Center for Child Health and Development, Tokyo, Japan.
Junichi HaraOsaka City General Hospital, Osaka, Japan.ORCID 0000-0002-6798-1558
Uwe R KordesUniversity Medical Center Eppendorf, Hamburg, Germany.ORCID 0000-0001-6375-2320
Santhosh A UpadhyayaDepartment of Oncology, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-6101-149X
Felix SahmDepartment of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.ORCID 0000-0001-5441-1962
Eric BouffetThe Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-6832-6539
Roger J PackerChildren's National Medical Center, Washington, DC.
Olaf WittHopp Children's Cancer Center (KiTZ), German Cancer Research Center (DKFZ), Heidelberg University Hospital, Heidelberg, Germany.
Larissa SandalicJohnson & Johnson, Basel, Switzerland.
Agnieszka KielochNovartis Pharma AG, Basel, Switzerland.
Mark RussoNovartis Pharmaceuticals Corporation, East Hanover, NJ.ORCID 0000-0002-5403-3989
Kenneth J CohenThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.ORCID 0000-0001-9193-9344
Investigators involved in the high-grade glioma cohort
German Cancer Research Center · DEGreat Ormond Street Hospital · GBSt. Jude Children's Research Hospital · USUniversität Hamburg · DESidney Kimmel Comprehensive Cancer Center · USChildren's National · USJohnson & Johnson (Switzerland) · CHNational Center For Child Health and Development · JPNovartis (Switzerland) · CHOsaka City General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose

methodsThis phase II study evaluated dabrafenib plus trametinib in patients with relapsed/refractory

resultsA total of 41 pediatric patients with previously treated

conclusionIn relapsed/refractory

Indexed as

GliomaMelanomaAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsChildHumansImidazolesMutationOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonesBRAF protein, humandabrafenibImidazolesOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinib

Identifiers

PMID37643378
PMCPMC10666989
OpenAlexW4386244466

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.